DOCSLIB.ORG

Fatal-Side-Effects-Medicine-Patents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fatal-Side-Effects-Medicine-Patents Fatal Side Effects: Medicine Patents under the Microscope 1st February 2001 Oxfam GB is a member of Oxfam International. Registered charity no. 202918 2 Contents Acknowledgements iii Oxfam GB's Health Programme iv Summary 1 Introduction 1 The health crisis 2 How much will the new patent rules increase prices? 2 Is TRIPS 'flexible' enough, and are the public-health safeguards adequate? 3 Will patenting in developing countries stimulate research into the diseases of poverty? 5 Is TRIPS good for development and poverty reduction? 6 The IP that TRIPS does not protect 6 Corporate social responsibility 7 Oxfam's principal recommendations 7 1. Background 9 Introduction 9 What is a patent, and what do World Trade Organisation (WTO) patent rules do? 9 Why are patents a health issue? 10 The development damage of excessive IP protection 12 Trade rules are loaded against the poor 13 2. The health crisis in developing countries 14 The burden of disease 14 Who pays for the medicines? 15 3. The impact of WTO patent rules on access, prices, and local industry 16 The new generation of medicines 17 Effective patent duration under TRIPS 17 Price differences 18 TNC views on the relation between prices and patents 19 The effect of patent systems on industry as a whole 20 4. The small print of WTO rules, and the political realities 21 What are the safeguards in TRIPS to protect public health? 22 Compulsory licensing 23 Parallel importing 24 Does this worsen the problem of sub-standard and counterfeit drugs? 24 How will the 'grey areas' be defined? 25 TRIPS plus: at the mercy of monopoly 25 Are transition periods the answer? 27 Can price controls and bulk purchasing help? 27 5. The relationship between patents and pharmaceutical R&D 28 What is not researched by pharmaceutical TNCs … 29 How patents can discourage socially useful research 29 How strong patenting can block research 30 Who really pays for research? 31 Technology transfer 31 i Contents 6. Medical bio-piracy in developing countries 32 7. The need for government action on health needs 34 Invest heavily in research 34 Who should do the research? 35 Complementary policies 35 8. The need for company action 36 Corporate philanthropy 36 Tiered, or differential, pricing 36 Policy influencing 37 9. Patent politics 38 Who makes the rules? 38 Who polices the rules? 38 Which governments want to change the rules … 39 … and which do not? 40 Public opinion 41 Who is responsible in London, Brussels, Geneva, and Washington, and in the boardrooms? 41 10. Policy recommendations 42 At the WTO 42 Patent rules at the national level 44 International action to develop new medicines, and improve procurement and delivery 44 At the WHO 45 The role of industry 45 Annexe: Selected articles of the 1994 WTO Agreement on Trade-Related Aspects of Intellectual Property (TRIPS) 46 Bibliography 50 Endnotes 54 ii Acknowledgements This report was produced by the Policy Department of Oxfam (Great Britain) as part of the ‘Cut the Cost of Medicines’ Campaign. The principal authors were Michael Bailey, Ruth Mayne, and Dr Mohga Smith. Oxfam gratefully acknowledges comments on drafts from Francisco Cannabrava (Brazil Mission in Geneva), Prof. Carlos Correa (University of Buenos Aires), Dr Peter Drahos (Queen Mary College, London), Nathan Ford (Médecins Sans Frontières - MSF), Daphne Fresle (World Health Organisation/Essential Drugs and other Medicines - WHO/EDM), David Grogan (industry analyst), Andrew Herxheimer (past Chairman of the International Society of Drug Bulletins), Rashid Kaukab (South Centre), Derek King (London School of Economics), Patrick Krappie (Mission of the Republic of South Africa in Geneva), Sol Picciotto (Lancaster University), Dr Peter Poore (public health consultant), Dr Jonathan Quick (WHO/EDM), Philippa Saunders (Essential Drugs Project), Matthew Stilwell (Centre for International Environmental Law), Alan Story (Kent University Law School), Sir John Sulston (co-founder of the Human Genome Project), Ellen T’Hoen (MSF), Anna Thomas (Voluntary Service Overseas - VSO), Bas van der Heide (Health Action International - HAI Europe), German Velasquez (WHO/EDM), Dr Gill Walt (London School of Hygiene and Tropical Medicine). Oxfam is also grateful to industry representatives and officials of the UK government, the European Commission and the World Trade Organisation for information and observations. Commentators do not necessarily share the views expressed in the paper. Oxfam has simultaneously issued two other publications as part of this Campaign: a shorter report entitled ‘Patent Injustice: How World Trade Rules Threaten the Health of the Poor’; and 'Dare to Lead', an analysis of the responsibilities towards the developing world of GlaxoSmithKline, the UK-based pharmaceuticals company. All three publications and further information on the Campaign are available from Oxfam’s website (www.oxfam.org.uk/cutthecost) or from Anni Long ([email protected]), tel no: +44 (0)1865 312127, fax no: +44 (0)1865 312245. iii Oxfam GB’s health programme Oxfam GB’s health programme addresses five broad themes: access to basic health services (including the issue of financing), access to essential medicines, access to water and sanitation, responding to HIV/AIDS, and health programmes in schools. This work focuses on reducing inequities, including those based on gender, and improving the appropriateness and quality of services. The programme spreads across more than 25 countries. Local projects support some of the most marginalised and impoverished groups. Others address the health needs of communities affected by conflict or natural disasters. Drawing on this experience and on research findings, Oxfam seeks to work with others to change policies, practices, ideas, and beliefs that affect poor people’s health. In India, Oxfam’s HIV/AIDS programme aims to increase treatment, care, and support for those infected and affected, as well as raising public awareness about the disease, while in Southern Africa we are piloting programmes to integrate responses to HIV/AIDS into development work. In Bangladesh, Sri Lanka, Ethiopia, Somaliland, South Sudan, and Liberia, Oxfam supports the rehabilitation of community health centres and the development of basic services, including medicine supply. In the Caucasus, the programme involves training health workers, improving access to essential drugs, and the development of community health insurance schemes. The Network for Consumer Protection, an Oxfam partner in Pakistan, promotes people’s access to, and the rational use of, essential drugs. In Afghanistan, Oxfam has ensured that basic health services have been made available to remote communities in the highlands. Oxfam GB is widely known for its public health work in emergencies. The rapid supply of clean water to populations displaced from their own homes is vital, and Oxfam GB has particular expertise in this area. In recent years, major programmes have been established in the Great Lakes Region of Central Africa, in the Balkans, in Angola, and in the State of Orissa in India. iv Fatal Side Effects: Medicine Patents under the Microscope Summary Introduction Every week, 200,000 people die of infectious diseases, the great majority of them women, men, and children living in poverty in the developing world. Global patent rules agreed at the World Trade Organisation (WTO) in 1994 are deepening this public-health crisis by increasing the cost of medicines. In this report, Oxfam argues that governments must amend the rules now to ensure that impoverished people have access to the medicines they so desperately need, at prices they can afford. This demand is at the centre of a public campaign launched by Oxfam in February 2001. The WTO rules, laid down in the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), were introduced after sustained lobbying by transnational corporations (TNCs). The Agreement obliges the member countries to grant at least 20-year patent protection in all fields of technology, including medicines. This enables already powerful Northern pharmaceutical TNCs to consolidate their market domination on a global scale. Longer patent periods will delay the appearance of the low-cost generic equivalents that traditionally supply developing-country needs – only the expensive, patented version of a new medicine will be available. At a time when millions of people are already unable to afford essential medicines, and when public health is threatened by a combination of new diseases and drug-resistant variants of old killers, WTO rules will further reduce access to modern medicines for poor people, and lead to unnecessary death and suffering. The controversy surrounding the price of patented HIV/AIDS drugs in Southern Africa has already drawn public attention to this issue. This report is structured as follows. Section 1 explains briefly how the WTO patent rules work and how they will affect the price of medicines in developing countries. It also sets out Oxfam’s concerns about the wider negative effects of the rules, and the way in which management of the international trading system puts corporate interests before poverty reduction. Section 2 describes the health crisis in developing countries. Section 3 examines the likely effect of WTO patent rules on the price of medicines and on local pharmaceutical industries. Section 4 looks in more detail at WTO rules and their implementation in developing countries, giving Oxfam’s assessment of the ‘flexibility’ that supposedly enables governments to ensure access to affordable medicines, and examining the problem of ‘TRIPS plus’ systems. The issue of whether high levels of patent protection will stimulate pharmaceutical research and development (R&D) relevant to developing countries is considered in Section 5. The relationship between TRIPS and the problem of bio-piracy in the pharmaceutical field is addressed in Section 6. Section 7 deals with the need for governments to fill the gaps in pharmaceutical research and increase health-sector support, while Section 8 looks at what companies could do to make drugs more affordable.
Load more

Recommended publications
  • Annual Report 2013
    Annual Report 2013 “ Being active and having a positive outlook on life is what keeps me going every day.” Overview of 2013 “ Our performance in 2013 was defined by remarkable &R D output and further delivery of sustained financial performance for our shareholders.” Please go to page 4 for more More at gsk.com Performance highlights £26.5bn £8.0bn £7.0bn £5.2bn Group turnover Core* operating profit Total operating profit Returned to shareholders 6 112.2p 112.5p 13% Major medicines approved Core* earnings per share Total earnings per share Estimated return on R&D investment 10 6 1st 1st Potential phase III study starts in 2014/15 Potential medicines with phase III data in Access to Medicines Index Pharmaceutical company to sign AllTrials expected 2014/15 campaign for research transparency Front cover story Betty, aged 65, (pictured) has Chronic “ Health is important to me, Obstructive Pulmonary Disease (COPD). She only has 25% lung capacity. This means I try to take care of my she finds even everyday tasks difficult, but medicines and inhaled oxygen allow her to health with all the tools live as normal a life as she can. Betty’s mindset I have and do the best is to stay busy and active, so every week she goes to rehab exercise classes. that I can with it.” COPD is a disease of the lungs that leads to Betty, COPD patient, damaged airways, causing them to become North Carolina, USA narrower and making it harder for air to get in and out. 210 million people around the world are estimated to have COPD.
    [Show full text]
  • In This Section
    Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group.
    [Show full text]
  • GCE a Level 1083/01 BUSINESS STUDIES –
    GCE A level 1083/01 S15-1083-01 BUSINESS STUDIES – BS3 A.M. WEDNESDAY, 10 June 2015 2 hours 1083 010001 ADDITIONAL MATERIALS In addition to this examination paper, you will need: • a calculator; • a 12 page answer book. INSTRUCTIONS TO CANDIDATES Use black ink or black ball-point pen. Answer all the questions. Write your answers in the separate answer book provided. INFORMATION FOR CANDIDATES The number of marks is given in brackets at the end of each question. You are reminded that assessment will take into account the quality of written communication used in answers that involve extended writing in questions 4 and 5. You are reminded that questions 4 and 5 are synoptic and so will test understanding of the connections between different elements of the subject. © WJEC CBAC Ltd. AM*(S15-1083-01) 2 Study the information provided about GlaxoSmithKline plc and answer the questions that follow. BACKGROUND GlaxoSmithKline plc (GSK) is a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. It has three primary areas of business: pharmaceuticals, vaccines and consumer healthcare. Its consumer products include 5 Ribena, Macleans toothpaste, Panadol headache pills, Lucozade and Horlicks. The company can trace its history back to 1715 when Sylvanus Bevan established his pharmacy in Plough Court in London. In 1880, his descendants founded Burroughs Wellcome and Company which, eventually in 1995, merged with the Australian company Glaxo to form Glaxo Wellcome. The American branch of the business can trace its history back to 1830 when John K Smith 10 opened his first drugstore.
    [Show full text]
  • Pharmaceutical Giant Consolidates Worldwide Facilities Management Services
    CASE STUDY From 300 to 3: Pharmaceutical Giant Consolidates Worldwide Facilities Management Services Client: GlaxoSmithKline The Opportunity Matter: Outsourcing contract strategy, UK-headquartered GlaxoSmithKline (GSK) is a FTSE structuring and negotiation 100-listed research-based pharmaceutical company that employs 99,000 people in more than 100 countries. GSK Area of Law: Outsourcing has a seven percent share of the world medicine/medical Result: Significantly increased profits and efficiency product market and, through its consumer health division, for GSK by replacing more than 300 sells products under household-name brands like alli, worldwide service providers using unique Ribena, Horlicks, Lucozade, Aquafresh, Sensodyne contracts with a select number of global and Panadol. providers using standardised agreements. GSK has grown both organically and through acquisition, contracting service suppliers one at a time as the need arose. By the time it enlisted Pillsbury’s help, GSK’s facilities management services spanned 300 suppliers across multiple sites and product lines, each with its own locally developed service levels and pricing models. GSK sought to simplify its operating model with a stand- ardised, scalable solution with consistent, measurable service levels delivered through a few global providers. The Challenge The scale of the project added significant complexity to the lifecycle aspects of the arrangement—from strategy, due diligence, contracting and transition to operational management and global rollout. GSK selected
    [Show full text]
  • Bk Sans 005737.Pdf
    TABLE OF CONTENTS Procter & Gamble’s Earnings Per Share .3 Coca-Cola’s Earnings Per Share .3 Johnson & Johnson’s Earnings Per Share .4 United Continental’s Earnings Per Share .4 Ford Motor Company’s Earnings Per Share .5 Advance Micro Devices, Inc.’s Earnings Per Share .5 Compare Coca-Cola to Ford Motor Company .6 American Express Company .7 American Express Company Per Share Earnings History .8 The Bank of New York Mellon (BNY Mellon) .9 BNY Mellon EPS History / BNY Mellon BVPS History .10 Coca-Cola Company .11 ConocoPhillips .12 ConocoPhillips EPS History / ConocoPhillips BVPS History .13 Costco Wholesale Corporation .14 Costco EPS History / Costco BVPS History .15 GlaxoSmithKline .16 GSK’s brand-name products .17 GlaxoSmithKline’ Profile / GlaxoSmithKline’ History .18 Johnson & Johnson .19 Johnson & Johnson Per Share Book Value History .20 Kraft Foods, Inc .21 Kraft Foods EPS History / Kraft Foods BVPS History .22 Moody’s Corporation .23 Moody’s Corporation EPS History .24 Procter & Gamble Company .25 Procter & Gamble BVPS History .26 Sanofi S. A. .27 Sanofi A.S EPS ADR History / Sanofi A.S BVPS History .28 Torchmark Corporatio .29 Torchmark Corporation EPS History / Torchmark Corporation BVPS History .30 Union Pacific Corporation .31 Union Pacific Corporation NPM (Net Profit Margin) History .32 Union Pacific Corporation BVPS History / Union Pacific Corporation EPS History .32 U.S. Bancorp .33 U.S. Bankcorp EPS History / U.S. Bankcorp BVPS History .34 Wal-Mart Stores, Inc. .35 Walmart EPS History / Walmart BVPS History .36 Washington
    [Show full text]
  • Glaxosmithkline ITA – Wikipedia
    GlaxoSmithKline - Wikipedia https://it.wikipedia.org/wiki/GlaxoSmithKline GlaxoSmithKline Da Wikipedia, l'enciclopedia libera. GlaxoSmithKline plc (Borsa di Londra: GSK (https://it.finance.yahoo.com/q?s=GSK.L), NYSE: GSK GlaxoSmithKline plc (https://www.nyse.com/quote/XNYS:GSK)) è una società britannica operante nel settore farmaceutico, biologico, e sanitario. GlaxoSmithKline è una società di ricerca con un vasto Stato Regno Unito portafoglio di prodotti farmaceutici che comprendono Forma Società per azioni antinfettivi del sistema nervoso centrale (SNC), societaria respiratorio, gastrointestinale/metabolico, oncologico e vaccini. Inoltre ha molti prodotti per l'igiene del Borse Borsa di Londra: GSK consumatore tra cui prodotti per l'igiene orale, bevande valori (https://it.finance.yahoo.com nutrizionali e medicinali da banco. È presente in 37 /q?s=GSK.L) nazioni ed in Italia possiede una sede a San Polo di NYSE: GSK Torrile, vicino a Parma. A Verona la Glaxo nasce il 30 (https://www.nyse.com marzo 1932 con il nome di Società anonima italiana /quote/XNYS:GSK) Nathan Bompiani, antesignana dell'odierna GlaxoSmithKline; dall'anno 2010 il centro ricerche di ISIN GB0009252882 Verona è condiviso con Aptuit[1]. L'Italia è stato il primo (http://www.isin.org/isin- insediamento estero dell'azienda che presto prenderà il preview nome Glaxo, dal greco "Galaktos", a simboleggiare uno /?isin=GB0009252882) dei suoi primi prodotti: il latte in polvere. Fondazione 2000 dalla fusione tra Glaxo Wellcome e SmithKline Beecham Indice Sede Londra principale
    [Show full text]
  • Annual Report 2015
    Annual Report 2015 2015 saw substantial progress to accelerate new product sales growth and strengthen our Pharmaceuticals, Vaccines and Consumer Healthcare businesses Overview of 2015 Strategic report “ In 2015, we made substantial progress to accelerate new product sales growth, integrate new businesses in Vaccines and Consumer Healthcare and restructure our global Pharmaceuticals business. This progress means the Group is well positioned to return to core earnings growth in 2016.” Sir Andrew Witty, Chief Executive Officer Governance & remunerationPerformance Financial statements summary Investor information £23.9bn £10.3bn £5.7bn £3.9bn Group turnover Total operating profit Core operating profit Cash dividends paid (up 6% CER/up 1% CER (up >100% CER) a (down 9% CER/down 3% in 2015 pro-forma) a CER pro-forma)a £2.0bn 174.3p 75.7p 10 0 % New product sales b Total earnings per share Core earnings per share Markets now operating (up >100%) (up >100%, primarily (down 15% CER, primarily new commercial model reflecting impact of reflecting short-term dilution transaction gains) of the Novartis transaction)a ~40 20 ~13 % 1st Potential new medicines Potential to file up to Estimated internal In Access to Medicine and vaccines profiled at R&D 20 assets with regulators rate of return in R&D Index event, 80% of which have by 2020 in 2015 potential to be first-in-classc Footnotes a We use a number of adjusted measures to report the performance of our business, as described on page 54. These include core results, CER growth rates and pro-forma CER growth rates. A reconciliation of total results to core results is set out on page 62.
    [Show full text]
  • Review Scottish
    INNOVATION TECHNOLOGY HEALTHCARE PHARMACY Scottish Review BIOSIMILAR MEDICINES WHAT YOU NEED TO KNOW CPD AN UPDATE WORD ON THE STREET HOMELESSNESS AND PHARMACISTS DOLLY THE SHEEP A 20-YEAR LEGACY SUMMER SPECIAL 2017 HEALTH HAZARDS IN THE SPOTLIGHT ISSUE 116 - 2017 VISIT US AT WWW.SCOTHEALTHCARE.COM 5688 QIPP advertorial in Northern Ireland Healthcare Review (NIH) v1.qxp_QIPP Zeroderma advertorial 18/01/2017 13:43 Page 1 wIdER CHoICE, GREATER SAvINGS FRom THE ZERodERmA RANGE How much could you save on emollient prescribing? The Zeroderma emollient range offers a choice of four creams, one ointment, Survey shows benefits of ® 19% Zerodouble Emollient Gel cost saving one gel and two bath additives - per pack providing complete emollient therapy Results from a recent survey with over 300 members of ® for moisturising, washing and bathing. the Psoriasis Association using Zerodouble emollient Gel showed that 97% liked the feel of Zerodouble Gel, 91% All Zeroderma products are gentle on said it was as good as or better than their current emollient the skin and do not contain the harmful and 84% wanted to continue using Zerodouble Gel. irritant sodium lauryl sulfate (SlS). Zeroderm® ointment – convenient 37% Zeroderma products are similar in formulation cost saving to around 50% of emollients currently 3-in-1 emollient therapy per pack prescribed by CCGs and offer cost savings SLS-free Zeroderm® Ointment provides a rich of up to 37%, with no compromise on 3-in-1 emollient for the management of eczema and dry skin conditions. Zeroderm Ointment can patient care. Around 75% of formularies and be used as a skin cleanser, a bath additive and as a leave-on moisturiser.
    [Show full text]
  • GSK Annual Report 2005 01 However, Addressing This Challenge Is Something GSK Cannot “The Tragedies During the Year Brought Home to Me the Extent Do Alone
    Annual Report 2005 Corporate Website brochure About us Meeting global challenges Our products Commitment to innovation Your health Access to medicines Responsibility Therapy areas In the community Our mission Research & Development A better future Investors What would Media centre you like to know Careers about GSK? www.gsk.com Corporate Annual GlaxoSmithKline Annual Report 2005 responsibility review report Access to medicines An interview with Research and innovation the Chairman and CEO human being Ethical conduct Focus on the patient Employees Annual The year of the vaccine Human rights Growing brands Environment report Powering performance Community investment Performance highlights Business operating review Summary remuneration report An interview with Corporate governance the Chairman and CEO Summary financial statements Financial summary Shareholder information Description of business Chairman and CEO’s Corporate governance closing letter Remuneration report Operating and financial review and prospects Financial statements Notes to the financial statements Investor information Do more, feel better, live longer Head Office and Registered Office GlaxoSmithKline plc 980 Great West Road Designed by CGI London. Brentford, Middlesex TW8 9GS Printed by The Midas Press in the UK. The paper used in the United Kingdom production of this document is made from pulps harvested Tel: +44 (0)20 8047 5000 from sustainable forests, also using sawmill residues and www.gsk.com forest thinnings. It is elemental chlorine-free. Do more, feel better, live longer “Discovering important medicines eradicating diseases, improving the quality of people’s lives and making medicines available to a greater number of people This is what we do – and what we do matters to people.” JP Garnier (left) and Sir Christopher Gent (right) “Thanks to the efforts of our employees around the world, 2005 was a very successful year for GSK.
    [Show full text]
  • 61808065.Pdf
    Internship Report “Understanding Current HFD Market Dynamics” Submitted To: Ms. Nusrat Hafiz Lecturer, BRAC Business School BRAC University. Submitted By: Md.Azimul Islam Student ID: 12304059 BRAC Business School BRAC University. BRAC University Date of Submission: 2nd May, 2016 2 | P a g e Letter of transmittal 2nd May, 2016 Ms. Nusrat Hafiz Lecturer, BRAC Business School BRAC University, Sub: Submission of final internship report. Dear Ma’am, I am pleased to submit my Internship Report on “Understanding Current HFD Market Dynamics”. This report was part of my assignment during my tenure at GlaxoSmithKline Bangladesh Limited. The report also includes a review of my job duties and experiences as a Marketing Intern. In the end I have included some of my recommendations regarding the critical points in the processes. I am submitting my internship report and I will be grateful enough if you kindly accept this. Your consideration will motivate me in the future to write better reports. Sincerely Yours, Md.Azimul Islam Student ID: 12304059 BRAC Business School BRAC University. 3 | P a g e Acknowledgement Writing a research paper is always the most challenging part of a student’s life. It was the most important academic contribution by me. However, this would not have been possible without the encouragement and support of a few people. I am personally indebted to some people who assisted me in my endeavor. Here I take this opportunity to display my gratitude towards them. First, I would also like to express my gratitude to my University internship supervisor, Ms. Nusrat Hafiz for her kind support and instruction for making this report more meaningful.
    [Show full text]
  • Glaxosmithkline
    GlaxoSmithKline 2012 criminal and civil settlement Overview In July 2012, GSK pleaded guilty in the United States to criminal charges, and agreed to pay US$3 billion, in what was the largest settlement until then between the Justice Department and a drug company. The US$3 billion included a criminal fine of US$956,814,400 and forfeiture of US$43,185,600. The remaining US$2 billion covered a civil settlement with the government under the False Claims Act. The investigation was launched largely on the basis of information from four whistleblowers who filed qui tam (whistleblower) lawsuits against the company under the False Claims Act.[9] The charges stemmed from GSK's promotion of the anti-depressants Paxil (paroxetine) and Wellbutrin (bupropion) for unapproved uses from 1998 to 2003, specifically as suitable for patients under the age of 18, and from its failure to report safety data about Avandia (rosiglitazone), both in violation of the Federal Food, Drug, and Cosmetic Act. Other drugs promoted for unapproved uses were two inhalers, Advair (fluticasone/salmeterol) and Flovent (fluticasone propionate), as well as Zofran (ondansetron), Imitrex (sumatriptan), Lotronex (alosetron) and Valtrex (valaciclovir).[9] The settlement also covered reporting false best prices and underpaying rebates owed under the Medicaid Drug Rebate Program, and kickbacks to physicians to prescribe GSK's drugs. There were all-expenses-paid spa treatments and hunting trips for doctors and their spouses, speakers' fees at conferences, and payment for articles ghostwritten
    [Show full text]
  • Glaxosmithkline Annual Report 2004
    Annual Report 2004 New challenges New thinking Do more, feel better, live longer Mission Our global quest is to improve the quality of human life by enabling people to do more, feel better and live longer. Our Spirit We undertake our quest with the enthusiasm of entrepreneurs, excited by the constant search for innovation. We value performance achieved with integrity. We will attain success as a world class global leader with each and every one of our people contributing with passion and an unmatched sense of urgency. Strategic Intent We want to become the indisputable leader in our industry. GlaxoSmithKline plc is an English public limited company. Business segments It shares are listed on the London Stock Exchange and the GlaxoSmithKline operates principally in two industry New York Stock Exchange. segments: • Pharmaceuticals (prescription pharmaceuticals and History and development of the company vaccines) GlaxoSmithKline plc, and its subsidiary and associated • Consumer Healthcare (over-the-counter medicines, undertakings, constitute a major global healthcare group oral care and nutritional healthcare). engaged in the creation, discovery, development, manufacture and marketing of pharmaceutical and Annual Report and Review consumer health-related products. This report is the Annual Report of GlaxoSmithKline plc GlaxoSmithKline has its corporate head office in London. for the year ended 31st December 2004, prepared in It also has operational headquarters in Philadelphia and accordance with United Kingdom requirements. Research Triangle Park, USA, and operations in some A summary report on the year, the Annual Review 2004, 116 countries, with products sold in over 125 countries. intended for the investor not needing the full detail of The principal research and development (R&D) facilities the Annual Report, is produced as a separate document.
    [Show full text]